File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective

TitleManagement of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
Authors
Issue Date2015
Citation
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, v. 33 n. 29, p. 3356-3364 How to Cite?
AbstractNasopharyngeal carcinoma of the undifferentiated subtype is endemic to southern China, and patient prognosis has improved significantly over the past three decades because of advances in disease management, diagnostic imaging, radiotherapy technology, and broader application of systemic therapy. Despite the excellent local control with modern radiotherapy, distant failure remains a key challenge. Advances in molecular technology have helped to decipher the molecular pathogenesis of nasopharyngeal carcinoma as well as its etiologic association with the Epstein-Barr virus. This in turn has led to the discovery of novel biomarkers and drug targets, rendering this cancer site a current focus for new drug development. This article reviews and appraises the key literature on the current management of nasopharyngeal carcinoma and future directions in clinical research.
Persistent Identifierhttp://hdl.handle.net/10722/220026
ISSN

 

DC FieldValueLanguage
dc.contributor.authorLee, WMA-
dc.contributor.authorMa, BB-
dc.contributor.authorNg, WT-
dc.contributor.authorChan, AT-
dc.date.accessioned2015-10-16T06:16:29Z-
dc.date.available2015-10-16T06:16:29Z-
dc.date.issued2015-
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, v. 33 n. 29, p. 3356-3364-
dc.identifier.issn0732-183x-
dc.identifier.urihttp://hdl.handle.net/10722/220026-
dc.description.abstractNasopharyngeal carcinoma of the undifferentiated subtype is endemic to southern China, and patient prognosis has improved significantly over the past three decades because of advances in disease management, diagnostic imaging, radiotherapy technology, and broader application of systemic therapy. Despite the excellent local control with modern radiotherapy, distant failure remains a key challenge. Advances in molecular technology have helped to decipher the molecular pathogenesis of nasopharyngeal carcinoma as well as its etiologic association with the Epstein-Barr virus. This in turn has led to the discovery of novel biomarkers and drug targets, rendering this cancer site a current focus for new drug development. This article reviews and appraises the key literature on the current management of nasopharyngeal carcinoma and future directions in clinical research.-
dc.languageeng-
dc.relation.ispartofJournal of clinical oncology : official journal of the American Society of Clinical Oncology-
dc.titleManagement of Nasopharyngeal Carcinoma: Current Practice and Future Perspective-
dc.typeArticle-
dc.identifier.emailLee, WMA: awmlee@hkucc.hku.hk-
dc.identifier.authorityLee, WMA=rp02056-
dc.identifier.doi10.1200/jco.2015.60.9347-
dc.identifier.pmid26351355-
dc.identifier.hkuros265754-
dc.identifier.volume33-
dc.identifier.issue29-
dc.identifier.spage3356-
dc.identifier.epage3364-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats